8-K current report · filed Nov 12, 2026

Pacira BioSciences, Inc. (PCRX) 8-K Current Report: November 12, 2026

Item 7.01PCRX overview

Short answer

Pacira BioSciences, Inc. (PCRX) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 7.01 (Regulation FD Disclosure). Ninth Circuit reversal reinstates Pacira’s royalty obligation for EXPAREL manufactured using the 200-liter process.

Pacira BioSciences, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Ninth Circuit reversal reinstates Pacira’s royalty obligation for EXPAREL manufactured using the 200-liter process
  • District Court must recalculate RDF’s pre-judgment interest owed on 45-liter EXPAREL royalties
  • Prior $28.3 million cash recovery from RDF now subject to litigation-related uncertainty
  • Pacira evaluating legal options, with final financial impact currently unpredictable

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Pacira BioSciences, Inc. 8-K filings

Get the next PCRX 8-K as it lands

Follow PCRX for push alerts, or ask the research agent what this filing means.